CYAD Price Targets and Analyst Ratings NASDAQ:CYAD
CYAD Forecast. What You Should Know.
CYAD Historical Ratings and Targets
About Celyad SA
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical... CYAD Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.